Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/237"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1292"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:content	"Effects of Voriconazole on Other Drugs In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
dc:creator	"boycer"
dc:date	"09/24/2009 15:10:02"
rdfs:seeAlso	?:ce3ef5cf-3087-4d92-9d94-9eb8287228db

The resource appears as object in one triple:

{ voriconazole_has_metabolite_voriconazole-N-oxide, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1292 }

Context graph